Bryan Armstrong's company, NewLimit, closed a $500 million funding round.

The Right to Try Act, passed during the first Trump administration, grants terminally ill patients access to experimental therapeutics.

Longevity-focused companies like BioAge often have to pivot to a traditional biotech model, focusing on a specific disease, to secure later-stage funding.